Clinical trials: Endometrial Cancer Stage II
Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
A Study to Assess the Efficacy and Safety of ABTL0812
A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.
- Trial name
- Endolung (NCT03366480)
- Testing
- ABTL0812 in combination with paclitaxel and carboplatin
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Ability Pharmaceuticals SL
PTCH1 or SMO Activated Solid and Hematologic Tumors
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT02002689)
- Testing
- LDE225
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Endometrial Cancer
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab…
- Trial name
- NCT05112991
- Testing
- Envafolimab+Lenvatinib, Envafolimab
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.
- Trial name
- NCT00910091
- Testing
- BN83495, Megestrol Acetate (MA)
- Where
- 54 sites in Belgium, Czechia and 10 more
- Volunteers
- 73 people
- Sponsor
- Ipsen
Endometrial Carcinoma
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
- Trial name
- NCT00334295
- Testing
- Fulvestrant
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Cervical Cancer, Endometrial Cancer
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
This Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab ± bevacizumab) in patients with recurrent or metastatic…
- Trial name
- NCT07054567
- Testing
- BL-B01D1, Pembrolizumab, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Recurrent Endometrial Cancer
Study of ART0380 in Patients With Biologically Selected Solid Tumors
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein…
- Conditions
- Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
- Trial name
- ARTIST (NCT05798611)
- Testing
- ART0380
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Artios Pharma Ltd
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Solid Tumor, NSCLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
This is a multicenter, open-label, dose-escalation and efficacy/safety Phase I/II study to assess RP2D, safety, tolerability and anti-tumor activity of Sintilimab + afuresertib + nab-paclitaxel or docetaxel administered as a…
- Conditions
- Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT05383482
- Testing
- Afuresertib, Nab paclitaxel, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- Laekna Limited
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Endometrial Cancer
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .
- Trial name
- NCT01111461
- Testing
- Lenvatinib
- Where
- 78 sites in United States, Belgium and 6 more
- Volunteers
- 133 people
- Sponsor
- Eisai Inc.
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Endometrial Cancer
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line…
- Trial name
- NCT01289041
- Testing
- BKM120
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Endometrial Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.
- Trial name
- NCT04574284
- Testing
- TQB2450, Anlotinib
- Where
- 36 sites in China
- Volunteers
- 170 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer Recurrent
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
This was a Phase 2, Simon two-stage, non-randomized, open-label, 2-arm trial of dordaviprone (ONC201) in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.
- Trial name
- NCT03485729
- Testing
- Dordaviprone (ONC201)
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Endometrial Cancer
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
This is an open label and single arm study to investigate the safety and efficacy of BEZ235 in adult women with endometrial carcinoma whose disease progressed (or recurred) while on or after first-line antineoplastic treatment…
- Trial name
- NCT01290406
- Testing
- BEZ235
- Where
- 59 sites in United States, Brazil and 10 more
- Sponsor
- Novartis Pharmaceuticals
Leiomyosarcoma, Liposarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
- Trial name
- NCT06277154
- Testing
- MASCT-I, Doxorubicin, Ifosfamide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- HRYZ Biotech Co.